Literature DB >> 4053025

Tumor cell generation of thrombin via functional prothrombinase assembly.

L VanDeWater, P B Tracy, D Aronson, K G Mann, H F Dvorak.   

Abstract

Prothrombinase affects the proteolytic conversion of prothrombin to thrombin and is the penultimate enzyme in the common coagulation pathway. Prothrombinase is a complex in which the proteinase, Factor Xa, a cofactor, Factor Va, and calcium are bound to a membrane surface to generate the active enzyme. Guinea pig line 1 and line 10 tumor cells, grown as primary cultures from ascites tumors or as cell lines in culture, provide a surface that interacts with coagulation Factor Va and Xa and with calcium ions to form this enzyme complex. Cultured human colorectal carcinoma cells (Colo 205) also participate in prothrombinase complex assembly and function. Prothrombinase generation was measured by following the kinetics of prothrombin conversion to thrombin. Thrombin generation was monitored continuously using the reversible thrombin inhibitor, dansylarginine N-(3-ethyl-1,5-pentanediyl)amide, which displays enhanced fluorescence upon binding to thrombin. Analyses of kinetic data indicate that the apparent dissociation constants (1-4 X 10(-10) mol/liter) and the number of Factor Va-Xa binding sites per tumor cell are comparable to values reported for human and bovine platelets, human lymphocytes, and monocytes. Guinea pig lymphocytes were also active, while erythrocytes were inactive, in the prothrombinase assay. Membrane vesicles, shed by guinea pig and human tumor cells into conditioned medium, also supported functional prothrombinase activity. Although earlier studies indicated that tumor cells may initiate coagulation, this is the first demonstration that tumor cells are competent to bring clotting to fruition by generating thrombin, a step essential to fibrin generation. These data suggest that tumor cells, in the presence of clotting initiators and appropriate coagulation factors, are sufficient to generate the fibrin deposited in solid tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053025

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 2.  Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.

Authors:  M Shoji; W W Hancock; K Abe; C Micko; K A Casper; R M Baine; J N Wilcox; I Danave; D L Dillehay; E Matthews; J Contrino; J H Morrissey; S Gordon; T S Edgington; B Kudryk; D L Kreutzer; F R Rickles
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 3.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

4.  Elevated thrombin-antithrombin III complex concentrations in patients with gynaecological malignancy.

Authors:  G Tatra; A Reinthaller
Journal:  Klin Wochenschr       Date:  1991-02-06

5.  Comparison between Ca2+-induced scrambling of various fluorescently labelled lipid analogues in red blood cells.

Authors:  David W C Dekkers; Paul Comfurius; Edouard M Bevers; Robert F A Zwaal
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

Review 6.  Vascular permeability, vascular hyperpermeability and angiogenesis.

Authors:  Janice A Nagy; Laura Benjamin; Huiyan Zeng; Ann M Dvorak; Harold F Dvorak
Journal:  Angiogenesis       Date:  2008-02-22       Impact factor: 9.596

7.  Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model.

Authors:  T C Carneiro-Lobo; S Konig; D E Machado; L E Nasciutti; M F Forni; I M B Francischetti; M C Sogayar; R Q Monteiro
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

8.  Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma.

Authors:  L F Brown; L Van de Water; V S Harvey; H F Dvorak
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

Review 9.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 10.  Vascular permeability factor (VPF, VEGF) in tumor biology.

Authors:  D R Senger; L Van de Water; L F Brown; J A Nagy; K T Yeo; T K Yeo; B Berse; R W Jackman; A M Dvorak; H F Dvorak
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.